Bioverativ Hits The Street Ready To Expand In Blood Disorders

Bioverativ will spin out from Biogen Feb. 1 as a biotech focused on rare blood disorders, particularly hemophilia. With two marketed drugs, a lifecycle management strategy and leverage to bring in new assets, CEO John Cox says the company is ready to go it alone.

Bioverativ Inc. – a new biotech focused on rare blood disorders – expects to deliver long-term growth by expanding the use of its two long-acting hemophilia drugs, a broad lifecycle management strategy and business development ambitions. The company is scheduled to spinout from Biogen Inc. as an independent company Feb. 1, with full trading to resume on NASDAQ under the symbol BVV the next day.

CEO John Cox talked about the company’s independent growth strategy during an interview Jan. 11 at the J.P. Morgan Healthcare...